AcuCort's warrant programme 2026/2029 has been fully subscribed. The fully subscribed programme demonstrates strong internal commitment and clear confidence in AcuCort's continued development. Through the programme, the four key personnel will also become shareholders in the company if the warrants are exercised.
"It is very encouraging to see the strong commitment from our key personnel. The fact that the programme is now fully subscribed, with four key employees choosing to invest in AcuCort, demonstrates strong confidence in the company and our continued development. We have a clear plan ahead and an engaged team that is helping to drive it forward," says Jonas Jönmark, CEO of AcuCort.
The warrant programme was approved by the Annual General Meeting of AcuCort on 27 May 2026 and comprises a maximum of 1,800,000 warrants. Of these, 1,500,000 warrants have been transferred to four key personnel in the company, while the remaining 300,000 warrants are reserved for future recruitment of key personnel.
Each warrant entitles the holder to subscribe for one new share in AcuCort AB during the period from 1 September 2029 up to and including 30 December 2029. The subscription price has been set at SEK 1.34 per share, corresponding to 200 per cent of the underlying share's average volume-weighted price on Spotlight Stock Market during the period from 28 May 2026 up to and including 11 June 2026. The subscription price is not below the quota value of the share.
Prior to subscription and subsequent transfer, the final warrant premium was set at SEK 0.07 per warrant, based on the Black-Scholes option pricing model. The calculation was performed by the independent valuation firm Öhrlings PricewaterhouseCoopers AB.
The complete terms and conditions of the warrant programme are available on AcuCort's website.
For further information:
Jonas Jönmark, CEO, AcuCort AB
Phone: 070 365 5400
E-mail: jonas.jonmark@acucort.se
About AcuCort AB (publ)
AcuCort has developed and is commercializing Zeqmelit®, a new rapidly dissolving oral film placed on the tongue, based on the well-known cortisone substance dexamethasone. The drug is a smart product in a new, innovative, patented, and user-friendly administration form primarily for the treatment of severe and acute allergic reactions, croup in children, nausea and vomiting during chemotherapy, and for the treatment of patients with COVID-19 requiring supplemental oxygen therapy. Zeqmelit® is approved in Sweden, Denmark, Norway, and Finland, where the product is also marketed. AcuCort (ticker: ACUC) is listed on the Spotlight Stock Market. Visit www.acucort.se for more information.